Form 4: Innoviva's Chief Accounting Officer, Marianne Zhen, Reports Stock and Option Grants

Marianne Zhen, Chief Accounting Officer of Innoviva, Inc., reports the acquisition of restricted stock units and non-statutory stock options.

Summary

• On February 24, 2025, Marianne Zhen, Chief Accounting Officer of Innoviva, Inc., reported the acquisition of 8,938 shares of common stock through a restricted stock unit (RSU) grant and 30,300 non-statutory stock options.
• The RSU grant vests 25% on February 20, 2026, with the remaining balance vesting in twelve equal installments every three months thereafter, contingent upon continuous service.
• The stock options also vest 25% on February 20, 2026, with the remaining balance vesting in twelve equal installments every three months thereafter, contingent upon continuous service.
• Both the RSU and stock options have accelerated vesting under specific change in control or involuntary termination scenarios.
• Following the reported transactions, Zhen beneficially owns 51,312 shares of common stock and 93,322 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The grants are a standard part of executive compensation and signal confidence in the company's future. There are no red flags or negative information in the filing.

Positives

• The grant of RSUs and stock options to the Chief Accounting Officer aligns her interests with those of the shareholders.
• The vesting schedule incentivizes continued service and commitment to the company's long-term success.
• The accelerated vesting provisions provide protection in the event of a change in control or involuntary termination.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance, but the vesting schedule of the equity grants suggests a focus on long-term value creation.

Industry Context

Equity grants are a common practice in the pharmaceutical and biotechnology industries to attract, retain, and incentivize key executives. The terms of these grants are generally aligned with industry standards.

Comparison to Industry Standards

• Equity compensation packages for Chief Accounting Officers in similar-sized pharmaceutical companies typically include a mix of stock options and restricted stock units.
• Vesting schedules of three to four years are standard in the industry to ensure long-term commitment.
• Change in control provisions are also common to protect executives in the event of a merger or acquisition.

Stakeholder Impact

• Shareholders may view the equity grants as a positive sign, aligning management's interests with their own.
• Employees may be motivated by the potential for future equity grants.
• The grants have no immediate impact on customers, suppliers, or creditors.

Key Dates

Keywords

Innoviva, Marianne Zhen, Chief Accounting Officer, stock options, restricted stock units, Form 4, beneficial ownership, vesting, INVA